Literature DB >> 10484010

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

E M Brunt1, C G Janney, A M Di Bisceglie, B A Neuschwander-Tetri, B R Bacon.   

Abstract

OBJECTIVE: Steatohepatitis is a morphological pattern of liver injury that may be seen in alcoholic or nonalcoholic liver disease. This pattern may occur with obesity, diabetes, the use of certain drugs, or the cause may be idiopathic. The well-recognized histopathological features of nonalcoholic steatohepatitis (NASH) include hepatocellular steatosis and ballooning, mixed acute and chronic lobular inflammation, and zone 3 perisinusoidal fibrosis. Currently, there are no systems for grading necroinflammatory activity or for staging fibrosis as exist for various other forms of chronic liver disease. The purpose of this study was to develop such a grading and staging system and was based on review of liver biopsies from 51 patients with nonalcoholic steatohepatitis from Saint Louis University Health Sciences Center.
METHODS: For determination of grade, 10 histological variables of activity were initially analyzed; an overall impression of mild, moderate, and severe was made and the variables considered to be most significant were used to develop the necroinflammatory grade.
RESULTS: The histological lesions considered to be significant were: steatosis, ballooning, and intra-acinar and portal inflammation. A staging score was developed to reflect both location and extent of fibrosis. The fibrosis score was derived from the extent of zone 3 perisinusoidal fibrosis with possible additional portal/periportal fibrosis and architectural remodeling. Fibrosis stages are as follows: Stage 1, zone 3 perisinusoidal fibrosis; Stage 2, as above with portal fibrosis; Stage 3, as above with bridging fibrosis; and Stage 4, cirrhosis.
CONCLUSION: We propose a grading and staging system that reflects the unique histological features of nonalcoholic steatohepatitis.

Entities:  

Mesh:

Year:  1999        PMID: 10484010     DOI: 10.1111/j.1572-0241.1999.01377.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  1052 in total

1.  NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis.

Authors:  Tarsila Ribeireiro; James Swain; Michael Sarr; Michael Kendrick; Florencia Que; Schuyler Sanderson; Anuradha Krishnan; Kimberly Viker; Kymberly Watt; Michael Charlton
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

2.  FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase.

Authors:  Alaric Falcon; Holger Doege; Amy Fluitt; Bernice Tsang; Nicki Watson; Mark A Kay; Andreas Stahl
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-06-08       Impact factor: 4.310

3.  Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease.

Authors:  Shikha S Sundaram; Ronald J Sokol; Kelley E Capocelli; Zhaoxing Pan; Jillian S Sullivan; Kristen Robbins; Ann C Halbower
Journal:  J Pediatr       Date:  2013-12-07       Impact factor: 4.406

4.  Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis.

Authors:  Lei Zhao; Maria Westerhoff; Rish K Pai; Won-Tak Choi; Zu-Hua Gao; John Hart
Journal:  Mod Pathol       Date:  2017-09-01       Impact factor: 7.842

5.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

Authors:  An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

6.  Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.

Authors:  N S Patel; M R Peterson; D A Brenner; E Heba; C Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2013-02-05       Impact factor: 8.171

7.  Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?

Authors:  Aliya Qayyum; Daryl M Chen; Richard S Breiman; Antonio C Westphalen; Benjamin M Yeh; Kirk D Jones; Ying Lu; Fergus V Coakley; Peter W Callen
Journal:  Clin Imaging       Date:  2009 Mar-Apr       Impact factor: 1.605

8.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

Authors:  Savino Bruno; Patrick Maisonneuve; Paola Castellana; Nicole Rotmensz; Sonia Rossi; Marco Maggioni; Marcello Persico; Alberto Colombo; Franco Monasterolo; Donata Casadei-Giunchi; Franco Desiderio; Tommaso Stroffolini; Virgilio Sacchini; Andrea Decensi; Umberto Veronesi
Journal:  BMJ       Date:  2005-03-03

Review 9.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

Review 10.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.